Table 1.
Serotonergic compounds inducing hypophagia
| Compound | Mechanism | Manufacturer (clinical status) | Selected reference |
|---|---|---|---|
| Inc. bioavail. | |||
| 5-HTP | 5HT precursor | — | Fletcher & Burton (1986) |
| Fenfluramine | SSRI and releaser | Servier (Withdrawn in 1997) | Halford et al. (2007) |
| Fluoxetine | SSRI | Eli Lilly (Withdrawn from Phase III) | Yen et al. (1987) |
| Paroxetine | SSRI | GlaxoSmithKline | Konkle et al. (2003) |
| Sertraline | SSRI | Pfizer | Nielsen et al. (1992) |
| Fluvoxamine | SSRI | Solvay Pharmaceuticals | Nonogaki et al. (2007) |
| Sibutramine | SNRI | Knoll/Abbott (Registered therapy) | Connoley et al. (1995) |
| 5-HT1 | |||
| CP-93, 129 | 5-HT1BR agonist | Pfizer | Macor et al. (1990) |
| CP-94, 253 | 5-HT1BR agonist | Pfizer | Koe et al. (1992) |
| RU-24969 | 5-HT1A/1BR agonist | Organon | Kennett et al. (1987) |
| 5-HT2C | |||
| Ro 60-0175 | agonist | Organon/Hoffman-La Roche | Martin et al. (1998) |
| Ro 60-0332 | agonist | Organon/Hoffman-La Roche | Martin et al. (1998) |
| Org-12962 | agonist | Organon (Phase II as antidepressant) | Nilsson (2006) |
| Org-37684 | agonist | Organon | Schreiber & De Vry (2002) |
| VER-3323 | agonist | Vernalis/Roche | Bentley et al. (2004) |
| VER-23779 | agonist | Vernalis/Roche | Somerville et al. (2007) |
| VER-2692 | agonist | Vernalis/Roche | Adams et al. (2006) |
| VER-5584 | agonist | Vernalis/Roche | Bentley et al. (2004) |
| VER-5593 | agonist | Vernalis/Roche | Bentley et al. (2004) |
| VER-8775 | agonist | Vernalis/Roche | Dourish et al. (2004) |
| BVT.933 | agonist | Biovitrum (Withdrawn from Phase IIb) | Svartengren et al. (2003a) |
| BVT-X | agonist | Biovitrum | Lam et al. (2008) |
| YM348 | agonist | Yamanouchi Pharm. | Hayashi et al. (2004a) |
| APD-356 | agonist | Arena Pharm. (Phase IIb completed) | Thomsen et al. (2008) |
| ATHX-105 | agonist | Athersys | Nilsson (2006) |
| WAY-163909 | agonist | Wyeth | Dunlop et al. (2005) |
| WAY-161503 | agonist | Wyeth | Rosenzweig-Lipson et al. (2006) |
| WAY-629 | agonist | Wyeth | Sabb et al. 2004 |
| LY448100 | agonist | Eli Lilly | Nilsson (2006) |
| IL-639 | agonist | Bristol Myers Squibb | Nilsson (2006) |
| PNU-22394 | agonist | Pharmacia (Phase I) | McCall et al. (2001) |
| 5-HT1/2 | |||
| mCPP | 5-HT1B/2CR agonist | Now distributed by multiple vendors | Kennett & Curzon (1988) |
| TFMPP | 5-HT1B/2A/2CR agonist | Now distributed by multiple vendors | Kennett et al. (1987) |
| MK-212 | 5-HT2R agonist | Now distributed by multiple vendors | Halford et al. (1997) |
| DOI | 5-HT2R agonist | Now distributed by multiple vendors | Simansky & Vaidya (1990) |
| 5-HT6 | |||
| BVT.74316 | antagonist | Biovitrum (Phase I completed) | Heal et al. (2008) |
| BVT.5182 | antagonist | Biovitrum | Svartengren et al. (2003b) |
| E-6837 | partial agonist | Esteve | Fisas et al. (2006) |
| PRX-07034 | antagonist | Epix (Phase I completed) | Shacham et al. (2006) |
| SB-271046 | antagonist | GlaxoSmithKline | Svartengren et al. (2004) |
| Ro 04–6790 | antagonist | Organon/Hoffman-La Roche | Woolley et al. (2001) |
| SB-399885 | antagonist | GlaxoSmithKline | Perez-Garcia & Meneses (2005) |
| SB-357134 | antagonist | GlaxoSmithKline | Perez-Garcia & Meneses (2005) |
Abbreviations: SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin and noradrenalin reuptake inhibitor.